|
PSMG4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.96119999995581E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.20220000000704E-05 |
| Normal-vs-Stage2 |
5.727400E-01 |
| Normal-vs-Stage3 |
2.66869999998587E-06 |
| Normal-vs-Stage4 |
8.35489999406747E-09 |
| Stage1-vs-Stage2 |
2.303800E-02 |
| Stage1-vs-Stage3 |
2.865200E-01 |
| Stage1-vs-Stage4 |
6.356600E-03 |
| Stage2-vs-Stage3 |
6.595100E-03 |
| Stage2-vs-Stage4 |
3.972600E-04 |
| Stage3-vs-Stage4 |
1.348430E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.68981999999485E-05 |
| Normal-vs-AfricanAmerican |
2.20759999169928E-09 |
| Normal-vs-Asian |
6.56849999947084E-07 |
| Caucasian-vs-AfricanAmerican |
1.193850E-04 |
| Caucasian-vs-Asian |
1.971180E-01 |
| AfricanAmerican-vs-Asian |
5.301300E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.193500E-04 |
| Normal-vs-Female |
1.54985999999413E-05 |
| Male-vs-Female |
4.123600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.31169999999059E-05 |
| Normal-vs-Age(41-60Yrs) |
1.969070E-04 |
| Normal-vs-Age(61-80Yrs) |
7.51700000000133E-05 |
| Normal-vs-Age(81-100Yrs) |
8.101600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.969200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.454600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.775600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.597000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.640400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.591000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.350400E-02 |
| Classical-VS-Follicular |
1.05350000001447E-06 |
| Classical-VS-Other |
2.691200E-01 |
| Classical-VS-Normal |
5.65180013900601E-10 |
| Tall-VS-Follicular |
5.22309999695381E-08 |
| Tall-VS-Other |
1.470170E-01 |
| Tall-VS-Normal |
6.0653004840816E-10 |
| Follicular-VS-Other |
6.509600E-01 |
| Follicular-VS-Normal |
9.897400E-01 |
| Other-VS-Normal |
6.234400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.477740E-03 |
| Normal-vs-N1 |
7.97460000000472E-05 |
| N0-vs-N1 |
1.067210E-01 |
|
|
